Roy H. Rhodes, M.D., Ph.D.


Professor of Pathology and Laboratory Medicine, Neuropathology
UMDNJ-Robert Wood Johnson Medical School

Medical Education Building (MEB)
1 Robert Wood Johnson Place, Room 212
New Brunswick, NJ 08901


Phone: (732) 253-3137

Assistant: Gina Thomas
(732) 235-8120


Roy H. Rhodes, M.D., Ph.D., was trained at the Cajal Laboratory of Neuropathology at the Los Angeles County-University of Southern California Medical Center following graduate work in Anatomy, medical school, internship and anatomic pathology residency at USC, finishing in 1978.  Dr. Rhodes taught at the University of Tennessee, USC, Case Western Reserve University, the University of Manitoba, and presently at Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey.  His main interests resulting in publications have included developmental anatomy of the human eye, AIDS neuropathology, and aspects of infection, inflammation and neoplasia involving the central nervous system, as well as muscle pathology.

Research Interests

Performed statistical analysis on over a hundred cases of tumors or other lesions to show significant relationships. Currently available technology, including array comparative genomic hybridization as well as fluorescence in-situ hybridization and immunostaining, allows a deeper understanding for diagnosis and for classification. Sorting out these issues often has a direct and immediate relationship to prognosis and clinical management, such as with oligodendrogliomas and their chromosomal deletion status. Newly emerging brain tumor entities are being understood by use of the available technology. Laboratory methods help to show differences of emerging entities from current classification but also similarities so that some of these ÒnewÓ tumors can be understood as subcategories of traditional tumors. Therefore, cutting edge tumor analysis in the laboratory translates into the most appropriate diagnosis from which clinical management is planned. Clinical and laboratory information that together suggest a category for a Ònon-traditionalÓ brain tumor will go beyond the Òmalignant gliomaÓ moniker for increasing numbers of patients and this information requires sophisticated new laboratory methods now under development.

Cases Presented